Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sumitomo Dainippon Pharma Co ( (JP:4506) ) just unveiled an update.
Sumitomo Pharma Co., Ltd. announced a significant variance between its financial forecasts and actual results for the half-year ended September 30, 2025, and revised its financial forecasts for the year ending March 31, 2026. The company reported stronger-than-expected revenue and profit figures, driven by robust sales of ORGOVYX in North America and lower-than-anticipated expenses. This led to an upward revision of its full-year forecasts, reflecting continued strong sales and improved financial performance.
The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2100.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Dainippon Pharma Co., Ltd. is a pharmaceutical company based in Osaka, Japan, primarily engaged in the development and sale of therapeutic agents. The company focuses on the North American market, with significant sales in advanced prostate cancer treatments.
Average Trading Volume: 6,926,226
Technical Sentiment Signal: Buy
Current Market Cap: Yen679.4B
For a thorough assessment of 4506 stock, go to TipRanks’ Stock Analysis page.